Effectiveness and safety study of tezepelumab in adults & adolescent participants with severe asthma in the United States - PASSAGE

Study identifier:D5180C00032

ClinicalTrials.gov identifier:NCT05329194

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Multicenter, Single-arm, Open-label, Post-Authorization, Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under-Studied Populations in the United States (PASSAGE)

Medical condition

asthma

Phase

Phase 4

Healthy volunteers

No

Study drug

Tezepelumab

Sex

All

Actual Enrollment

285

Study type

Interventional

Age

12 Years - 130 Years

Date

Study Start Date: 29 Apr 2022
Estimated Primary Completion Date: 08 Jul 2025
Estimated Study Completion Date: 08 Jul 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria